TrialThe lancet. HIV2026

Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.

Elizabeth D Lowenthal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.